<DOC>
	<DOC>NCT02597387</DOC>
	<brief_summary>To study efficacy and safety of Mitoxantrone HCL Liposome Injection in patients with diffuse large B-cell lymphoma and lymphoma peripheral T cell.</brief_summary>
	<brief_title>Clinical Trial of Mitoxantrone HCL Liposome Injection in Patients With Relapsed DLBCL and PT/NKCLs</brief_title>
	<detailed_description>A Single-arm, Open, Multi-center Phase II Clinical Trial of Mitoxantrone HCL Liposome Injection in Subjects With Relapsed Diffuse Large B-cell Lymphoma and and Peripheral T/NK Lymphomas with dose of 20 mg/m2.</detailed_description>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>The subjects are voluntary and sign the informed consent form; ECOG score 0 to 2; The expected survival time ≥3 months; Diffuse large Bcell and peripheral T/NK cell nonHodgkin's lymphomas confirmed with histopathology, and the peripheral T/NK cell lymphomas that are only limited to the following types: peripheral Tcell lymphoma (not otherwise specified), angioimmunobl; Failure or relapse after at least once of systemic treatment, and patients who can not receive autologous peripheral blood stem cell transplantation The major diameter of a single measurable lesion ≥1.5 cm in at least one measurable lesion; An interval of at least four weeks after the target tumor was treated with chemotherapy, radiotherapy, biological therapy, stem cell transplantation or other study drugs; Subjects at childbearing age agree to take effective contraceptive measures during the study; blood pregnancy test result is negative (except infertility due to menopause or operation); Laboratory tests (blood routine, liver and kidney function) meet the following requirements: ANC≥ 1.5×109/L, for those with bone marrow involvement, ANC ≥ 1.0×109/L; PLT ≥ 75×109/L, for those with bone marrow involvement, PLT ≥ 50 × 109/L; Hb ≥ 9 g/dL; d) Cr) ≤ 1.5x ULN ; TBIL ≤ 1.5x ULN; AST or ALT ≤2.5 x ULN (for patients with liver metastases, ≤ 5 x ULN ). Pregnant or lactating women; An allergic history to anthracyclines or liposome drugs; Disease progression or recurrence after anthracycline treatment within six months before the enrollment;" Patients who once used mitoxantrone injection; Patients who have used doxorubicin (or pirarubicin) with the total cumulative dose&gt; 360mg/m2, or epirubicin with the total cumulative dose &gt; 600mg/m2; Left ventricular ejection fraction is &lt; 50% or &lt; the lower limit of normal; clinically significant QT interval prolongation (&gt;450ms in male, &gt;470ms in female); a past history of cardiac disease caused by anthracyclines; a history of severe heart disease; Concomitant treatment as other anticancer drugs are needed; Lymphoma involving the central nervous system; Clinically active infection that can significantly affect the clinical trial; Within 6 weeks after organ transplantation or major organ surgery; Those who are inappropriate to be enrolled as evaluated by the researchers.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>